查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462564

智慧胰岛素笔市场 - 按连结类型（蓝牙、NFC）、适应症（1 型糖尿病、2 型糖尿病）、配销通路（医院药房、零售药房、电子商务） - 全球预测，2024 年 - 2032 年

Smart Insulin Pens Market - By Connectivity Type (Bluetooth, NFC), Indication (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce) - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在先进糖尿病管理技术的日益普及以及人们对智慧笔优势的认识不断提高的推动下，2024年至2032年全球智慧胰岛素笔市场规模将以9.2%的CAGR成长。这些笔专注于加强糖尿病护理，提供使用者友好的功能并提高治疗依从性。它们的吸引力在于方便的胰岛素输送和根据血糖水平自动调整剂量。随着患者和医疗保健提供者认识到这些好处，智慧胰岛素笔产业将大幅扩张，推动糖尿病管理的创新和可及性。

例如，2023 年 12 月，Tandem Diabetes Care 推出了 t: slim X2 智慧胰岛素笔，旨在与 CGM 连接，根据血糖水平自动输送胰岛素。

智慧胰岛素笔产业根据连接类型、适应症、配销通路和地区进行细分。

由于全球 2 型糖尿病发生率不断上升，特别是在久坐生活方式和不健康饮食盛行的已开发国家，2 型糖尿病细分市场将在 2032 年建立稳固的立足点。智慧胰岛素笔提供便利、精准的胰岛素输送，满足第2型糖尿病患者有效自我管理的需求。随着人们对个人化医疗保健的日益关注以及数位健康解决方案的日益普及，2 型糖尿病领域将成为智慧胰岛素笔产业的关键驱动力。

到 2032 年，零售药房领域将获得相当大的智慧胰岛素笔市场份额，这主要是因为这些药房为寻求糖尿病管理解决方案的患者提供了便利和可及性。随着自我管理和胰岛素监测的趋势不断增长，零售药局在向广大消费者群体销售智慧胰岛素笔方面发挥关键作用。随着人们对智慧胰岛素笔优点的认识不断提高，可用性的增加将使零售药房领域成为市场成长和扩张的关键驱动力。

受糖尿病盛行率上升、先进医疗技术的日益采用以及该地区医疗基础设施不断扩大等因素的推动，到 2032 年，亚太地区智慧胰岛素笔市场将录得显着的CAGR。中国、印度和日本等国家处于采用创新糖尿病管理解决方案的前沿。随着对技术进步的高度重视以及对高效医疗保健解决方案不断增长的需求，亚太地区将成为新兴智慧胰岛素笔市场的关键贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 糖尿病盛行率上升
      • 技术进步
      • 增强糖尿病自我管理意识
    • 产业陷阱与挑战
      • 智慧胰岛素笔成本高
  • 成长潜力分析
  • 波特的分析
  • PESTEL分析
  • 报销场景
  • 监管环境
  • 技术景观
  • 未来市场趋势
  • 缺口分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按连结类型，2018 年 - 2032 年

  • 主要趋势
  • 蓝牙
  • 近场通讯

第 6 章：市场估计与预测：按指标划分，2018 年 - 2032 年

  • 主要趋势
  • 1 型糖尿病
  • 2型糖尿病

第 7 章：市场估计与预测：按配销通路，2018 年 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 电子商务

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Cambridge Consultants Ltd.
  • Eli Lilly and Company
  • Emperra GmbH
  • Jiangsu Delfu medical device Co., Ltd.
  • Medtronic plc
  • Novo Nordisk
  • Ypsomed Group
简介目录
Product Code: 8271

Global Smart Insulin Pens Market size will grow at a 9.2% CAGR from 2024 to 2032, fueled by the rising adoption of advanced diabetes management technologies and increasing awareness of the advantages of smart pens. With a focus on enhancing diabetes care, these pens offer user-friendly features and improved treatment adherence. Their appeal lies in their convenient insulin delivery and automated dosage adjustments based on blood sugar levels. As patients and healthcare providers recognize these benefits, the smart insulin pens industry will expand significantly, driving innovation and accessibility in diabetes management.

For instance, in December 2023, Tandem Diabetes Care introduced the t: slim X2 smart insulin pen, designed to connect with a CGM for automatic insulin delivery based on blood sugar levels.

The smart insulin pens industry is segmented based on connectivity type, indication, distribution channel, and region.

The type 2 diabetes segment will establish a substantial foothold by 2032, attributed to the rising incidence of type 2 diabetes globally, particularly in developed nations where sedentary lifestyles and unhealthy diets are prevalent. Smart insulin pens offer convenience and precise insulin delivery, appealing to the needs of type 2 diabetes patients for effective self-management. With a growing focus on personalized healthcare and the increasing use of digital health solutions, the type 2 diabetes segment will stand as a key driver in the smart insulin pens industry.

The retail pharmacies segment will garner a sizeable smart insulin pens market share by 2032, primarily due to the convenience and accessibility these pharmacies offer to patients seeking diabetes management solutions. With a growing trend toward self-administration and monitoring of insulin, retail pharmacies play a pivotal role in distributing smart insulin pens to a broad consumer base. This increased availability, in line with rising awareness about the benefits of smart insulin pens, will position the retail pharmacies segment as a key driver behind market growth and expansion.

Asia Pacific smart insulin pens market will record a noteworthy CAGR by 2032, propelled by factors such as the rising prevalence of diabetes, increasing adoption of advanced healthcare technologies, and the region's expanding healthcare infrastructure. Countries like China, India, and Japan are at the forefront of embracing innovative solutions for diabetes management. With a strong focus on technological advancements and a growing demand for efficient healthcare solutions, Asia Pacific will emerge as a key contributor to the burgeoning smart insulin pens market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast calculations
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of diabetes
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Enhanced awareness of self-management of diabetes
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of smart insulin pens
  • 3.3 Growth potential analysis
  • 3.4 Porter's analysis
    • 3.4.1 Supplier power
    • 3.4.2 Buyer power
    • 3.4.3 Threat of new entrants
    • 3.4.4 Threat of substitutes
    • 3.4.5 Industry rivalry
  • 3.5 PESTEL analysis
  • 3.6 Reimbursement scenario
  • 3.7 Regulatory landscape
  • 3.8 Technological landscape
  • 3.9 Future market trends
  • 3.10 GAP analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Connectivity Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Bluetooth
  • 5.3 NFC

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Type 1 diabetes
  • 6.3 Type 2 diabetes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Cambridge Consultants Ltd.
  • 9.2 Eli Lilly and Company
  • 9.3 Emperra GmbH
  • 9.4 Jiangsu Delfu medical device Co., Ltd.
  • 9.5 Medtronic plc
  • 9.6 Novo Nordisk
  • 9.7 Ypsomed Group